对多发性硬化症的疾病修饰和症状药物治疗的概述
Gloria Dalla Costa1, Letizia Leocani1,2, Mariaemma Rodegher2
1Vita Salute San Raffaele University, Milan, Italy.
Expert review of clinical pharmacology
|October 8, 2024
概括
早期,积极的疾病修饰疗法 (DMT) 可以改善多发性硬化症 (MS) 的预后. 然而,管理渐进性多发性硬化仍然具有挑战性,需要个性化药物和生物标志物洞察力,以获得更好的患者结果.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 是一种致残的自身免疫性疾病,其特征是炎症和退化.
- 早期和积极使用疾病修饰疗法 (DMT) 改善了MS患者的长期预后.
- 管理渐进的MS形式带来了持续的治疗挑战.
研究的目的:
- 对复发性复发性多发性硬化 (RRMS) 和渐进性多发性硬化 (MS) 的现有疾病修饰疗法 (DMT) 进行审查.
- 评估这些DMT的疗效,安全性和作用机制.
- 突出生物标志物在优化治疗策略和管理多发性硬化症症状中的作用.
主要方法:
- 在PubMed,Embase和Cochrane图书馆数据库中进行全面的文献搜索.
- 审查侧重于2000年1月至2024年1月的出版物.
- 分析MS管理中的治疗进展,安全概况和生物标志物应用.
主要成果:
- 在RRMS的治疗方面取得了重大进展,根据预后因素建议立即开始治疗.
- 进展性多发性硬化症的治疗选择仍然有限,这强调了对创新治疗的需求.
- 由生物标志物指导的个性化药物显示出提高MS治疗疗效和患者结果的潜力.
结论:
- 优化MS治疗需要及时干预和个性化的方法.
- 进一步的研究和创新对于开发进展性MS的有效疗法至关重要.
- 生物标志物是改进治疗决策和改善多发性硬化症的长期管理的关键.
相关概念视频
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:29Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
01:24Parkinson's Disease: Treatment
233
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
233
01:28Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K